Literature DB >> 12619108

The TP53 gene, tobacco exposure, and lung cancer.

Shinichi Toyooka1, Toshihide Tsuda, Adi F Gazdar.   

Abstract

Of the various genetic alterations in lung cancer, the abnormalities of the TP53 gene (p53) are among the most frequent and important events. Because of its importance, many aspects of TP53 have been studied, including preneoplastic lesions and TP53as a marker for early detection and prognosis and as a therapeutic option. We summarize recent knowledge of TP53 in lung cancer with a special emphasis on the relationship between smoking exposure (e.g, cigarette, etc.) and specific mutational pattern of TP53by analyzing the latest version of the International Agency for Research on Cancer (IARC) database on TP53 mutations in human cancer. Our analysis confirmed several other studies showing significant differences in the frequencies of G:C to T:A transversions between ever-smokers and never-smokers. Furthermore, when comparing the mutational spectrum by gender, important differences were noted between male and female never-smokers. We concluded that the previously noted G:C to T:A transversions were mainly due to female smokers having a high frequency of these changes compared to female never-smokers. There was no relationship between adenocarcinomas and squamous cell carcinomas independent of gender. We also examined the seven codons which have been previously identified as hot spots, that is, the sites of frequent G:C to T:A transversions in smoking-related lung cancers. However, there was no specific codon which was strongly related to smoke exposure despite a moderate relationship. We considered the term "warmspot" may be more appropriate. While mutations of TP53 are frequent in lung cancers, further investigation is necessary to understand their role for lung carcinogenesis, especially as they relate to gender differences, and to translate our laboratory knowledge to clinical applications. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619108     DOI: 10.1002/humu.10177

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  74 in total

1.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Authors:  L V Sequist; R S Heist; A T Shaw; P Fidias; R Rosovsky; J S Temel; I T Lennes; S Digumarthy; B A Waltman; E Bast; S Tammireddy; L Morrissey; A Muzikansky; S B Goldberg; J Gainor; C L Channick; J C Wain; H Gaissert; D M Donahue; A Muniappan; C Wright; H Willers; D J Mathisen; N C Choi; J Baselga; T J Lynch; L W Ellisen; M Mino-Kenudson; M Lanuti; D R Borger; A J Iafrate; J A Engelman; D Dias-Santagata
Journal:  Ann Oncol       Date:  2011-11-09       Impact factor: 32.976

2.  Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection.

Authors:  Yu-Min Shen; Andrea B Troxel; Srilakshmi Vedantam; Trevor M Penning; Jeffrey Field
Journal:  Chem Res Toxicol       Date:  2006-11       Impact factor: 3.739

3.  Formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dGuo) by PAH o-quinones: involvement of reactive oxygen species and copper(II)/copper(I) redox cycling.

Authors:  Jong-Heum Park; Sridhar Gopishetty; Lawrence M Szewczuk; Andrea B Troxel; Ronald G Harvey; Trevor M Penning
Journal:  Chem Res Toxicol       Date:  2005-06       Impact factor: 3.739

Review 4.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

Review 5.  Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis.

Authors:  S Wasswa-Kintu; W Q Gan; S F P Man; P D Pare; D D Sin
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

6.  Dachshund binds p53 to block the growth of lung adenocarcinoma cells.

Authors:  Ke Chen; Kongming Wu; Shaoxin Cai; Wei Zhang; Jie Zhou; Jing Wang; Adam Ertel; Zhiping Li; Hallgeir Rui; Andrew Quong; Michael P Lisanti; Aydin Tozeren; Ceylan Tanes; Sankar Addya; Michael Gormley; Chenguang Wang; Steven B McMahon; Richard G Pestell
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

7.  Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.

Authors:  Tien Hoang; Suzanne E Dahlberg; Alan B Sandler; Julie R Brahmer; Joan H Schiller; David H Johnson
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

8.  TP53 mutations in Korean patients with non-small cell lung cancer.

Authors:  Eung Bae Lee; Guang Jin; Shin Yup Lee; Ji Young Park; Min Jung Kim; Jin Eun Choi; Hyo Sung Jeon; Seung Ick Cha; Sukki Cho; Chang Ho Kim; Tae-In Park; Tae Hoon Jung; Ji-Woong Son; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

9.  Cellular and molecular phenotypes of proliferating stromal cells from human carcinomas.

Authors:  E P Kopantzev; N A Vayshlya; M R Kopantseva; V I Egorov; M Pikunov; M V Zinovyeva; T V Vinogradova; I B Zborovskaya; E D Sverdlov
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

10.  Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.

Authors:  Mitsuo Sato; Jill E Larsen; Woochang Lee; Han Sun; David S Shames; Maithili P Dalvi; Ruben D Ramirez; Hao Tang; John Michael DiMaio; Boning Gao; Yang Xie; Ignacio I Wistuba; Adi F Gazdar; Jerry W Shay; John D Minna
Journal:  Mol Cancer Res       Date:  2013-02-28       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.